This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schluep, M. Articles by Magistretti, P. J Search for Related Content PubMed PubMed Citation Articles by Schluep, M. Articles by Magistretti, P. J Social Bookmarking                         What's this?

In vitro cytokine profiles as indicators of relapse activity and clinical course in multiple sclerosis

Laboratoire de Recherche Neurologique de l'Institut de Physiologie et du, Universitéde Lausanne, Switzerland, Service de Neurologie du CHUV, Universitéde Lausanne, Switzerland

Guy van Melle

Institut Universitaire de Médecine Sociale et Préventive, Universitéde Lausanne, Switzerland

Hugues Henry

Laboratoire de Chimie Clinque, Faculté de Médecine, Universitéde Lausanne, Switzerland

Claudio Städler

Service de Neurologie du CHUV, Universitéde Lausanne, Switzerland

Béatrice Roth-Wicky

Laboratoire de Recherche Neurologique de l'Institut de Physiologie et du, Universitéde Lausanne, Switzerland

Pierre J Magistretti

Laboratoire de Recherche Neurologique de l'Institut de Physiologie et du, Universitéde Lausanne, Switzerland

In vitro production of tumor necrosis factor-a (TNF-a), interleukin-2 (IL-2), IL-4, IL-6, IL-10 and oligoclonal IgG (IgG OB) was evaluated in the aim to investigate their profile in correlation with multiple sclerosis (MS) clinical activity and clinical course. Whole blood stimulation with lipopolysaccharide or concanavalin A was performed in 61 patients presenting with relapsing-remitting, relapsing-progressive or chronic progressive MS; treatments received were: none, azathioprine (AZA), cyclosporin, cyclophosphamide, subcutaneous interferon-b 1a (IFN-b 1a) and corticosteroids (CST). The cinetics of cytokine production showed that (i) in the absence of treatment, TNF-a and IL-6 dropped respectively after and during the periods surrounding relapse, while IL-4 was increasing before and IL-10 after relapse; (ii) with AZA, TNF-a and IL-6 lowered before exacerbation, IL-4 prolonged high levels after and IL-10 before relapse; (iii) with IFN-b 1a, IL-10 was already increasing before relapse, and TNF-a was higher after relapse. When cytokine levels were analysed independently from MS clinical activity, the use of AZA inhibited IgG OB and TNF-a synthesis (P=0.002) but increased IL-4 (P=0.0024), whereas IFN-b 1a stimulated TNF-a and inhibited IgG OB and IL-4 production. CST inhibited TNF-a, IL-6, IL-4 and IgG OB synthesis. This study stresses both the weight of clinical parameters and of methodology used in results obtained in cytokine analysis in MS.

Key Words: multiple sclerosis • relapse activity • cytokines • IgG

Multiple Sclerosis, Vol. 4, No. 3, 198-202 (1998)
DOI: 10.1177/135245859800400321


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?